Literature DB >> 6766420

Effect of chenodeoxycholic acid on liver structure and function in man: a stereological and biochemical study.

M M Koch, M P Giampieri, I Lorenzini, A M Jezequel, F Orlandi.   

Abstract

Chenodeoxycholic acid (CDCA) is an effective treatment for dissolving gallstones but experimental studies have suggested that it might be hepatotoxic. The present study is concerned with a group of patients undergoing medical therapy for gallstones for periods of 30 days up to 14 months with CDCA (15 mg/kg/day). Routine functional tests, determination of some liver microsomal enzymes and stereological studies of the liver tissue have been performed and the data have been compared with those obtained before treatment. No significant changes were observed in the functional tests throughout the study. Also the microsomal mixed function oxidase system seemed unaffected by CDCA therapy. The histological features of the liver biopsies were not appreciably different from those observed prior to treatment. Although there were large interindividual variations, the volume density of parenchymal steatosis and of the lipocytes remained comparable in the ssme individual. The ultrastructural features noted in untreated subjects such as curled mitochondrial cristae, slight intracellular bile retention, increased surface density of the rough endoplasmic reticulum were still evident after 14 months of treatment. No additional changes were noted. These results show that no evidence of hepatotoxicity seems to develop in man under therapy with CDCA at the dose considered. But the structural abnormalities observed before treatment appear to persist even in subjects under long-term therapy.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6766420     DOI: 10.1159/000198409

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  5 in total

1.  A possible role of chenodeoxycholic acid and glycine-conjugated bile acids in fibrotic steatohepatitis in a dietary rat model.

Authors:  Xiaofang Jia; Yudai Suzuki; Hisao Naito; Husna Yetti; Kazuya Kitamori; Yumi Hayashi; Rina Kaneko; Mina Nomura; Yukio Yamori; Kei Zaitsu; Masashi Kato; Akira Ishii; Tamie Nakajima
Journal:  Dig Dis Sci       Date:  2014-01-22       Impact factor: 3.199

2.  Dissolving gall stones.

Authors:  M C Bateson
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-02

Review 3.  Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part II.

Authors:  W H Bachrach; A F Hofmann
Journal:  Dig Dis Sci       Date:  1982-09       Impact factor: 3.199

4.  Sulfation of lithocholate as a possible modifier of chenodeoxycholic acid-induced elevations of serum transaminase in patients with gallstones.

Authors:  J W Marks; S O Sue; B J Pearlman; G G Bonorris; P Varady; J M Lachin; L J Schoenfield
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

5.  Drug and treatment efficacy of chenodeoxycholic acid in 97 patients with cholelithiasis and increased surgical risk.

Authors:  T Tangedahl; W D Carey; D R Ferguson; S Forsythe; M Williams; K Paradis; N C Hightower
Journal:  Dig Dis Sci       Date:  1983-06       Impact factor: 3.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.